Liquidia and United Therapeutics settle six lawsuits over YUTREPIA
On October 13, 2026, Liquidia and United Therapeutics reached a global settlement resolving six lawsuits, including patent, trade-secret, contract and antitrust disputes. Liquidia will pay United Therapeutics and other parties a total of $380.7 million across 2026 and 2027. YUTREPIA will remain available for pulmonary arterial hypertension, while Liquidia is removing the pulmonary hypertension associated with interstitial lung disease indication from its label and will not appeal the related court ruling.
Why it matters
The agreement removes the litigation risk around continued YUTREPIA sales for pulmonary arterial hypertension but creates a substantial near-term cash obligation for Liquidia. United Therapeutics and related antitrust parties will receive settlement payments, while Liquidia expects to fund them with YUTREPIA revenue and cash on hand.
Key facts
- 1The settlement resolves all six pending lawsuits between Liquidia and United Therapeutics and related parties. stocktitan.net
- 2Liquidia’s total settlement obligation is $380.7 million, payable across 2026 and 2027. stocktitan.net
- 3Preliminary unaudited third-quarter YUTREPIA net product sales were $222.7 million, and cash and cash equivalents were $396.1 million as of September 30, 2026. stocktitan.net
- 4Liquidia agreed not to appeal the September 30, 2026, Delaware court ruling and submitted a label supplement removing the PH-ILD indication. stocktitan.net
- 5YUTREPIA will continue to be available without interruption for patients with pulmonary arterial hypertension. stocktwits.com
Open questions
- The materials do not agree on the detailed installment schedule: some report two $72.7 million installments, while another reports $145.4 million split into two installments, in addition to other payments.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.